the Supreme Court basically said. And it was and it split right the way you thought that it would, but it it split with the six conservatives on the court saying, OSHA doesn't have that authority to to do that. The administration doesn't have the authority and Congress hadn't actually established the kind of laws and the kind of foundation that it would take for ocean even, you know, consider trying to do that. So this is big. This takes this takes a major tool out of the toolbox. As far as, you know, the biden administration is concerned. They did allow the mandates to actually go into effect for for all those health care workers that work at establishments that that received Medicare and Medicaid funding. So that will at least impact, you know, the people in the health care professions. So unless the biden administration is going to go back to Congress and actually get Congress to actually pass some kind of legislation that would then allow it to, you know, come back and say, we have the cover of law now, I think this is probably gonna be a dead issue.
4th vaccine dose boosts antibodies, but likely not enough to prevent omicron breakthrough infections
![CNN logo]()
Updated: 10:18 AM EST Jan 18, 2022
Video above: SCOTUS blocks vaccine or test rule for businessEarly data out of Israel suggests that a fourth dose of either the Pfizer/BioNTech or Moderna coronavirus vaccine can bring an increase in antibodies 바카라 게임 웹사이트 more than what's been seen after a third dose 바카라 게임 웹사이트 but it still might not be enough to protect against breakthrough infections caused by the omicron variant."These are very preliminary results. This is before any publication, but we're giving it out since we understand the urgency of the public to get any information possible about the fourth dose," Dr. Gili Regev-Yochay, director of the Infection Prevention and Control Unit at Sheba Medical Center, told reporters during a virtual news conference Monday about the data."We have a follow-up of the Pfizer vaccine for two weeks now, and we have a follow-up of the Moderna vaccine just for one week at this time point. And what we see is that the Pfizer vaccine, after two weeks, you see an enhancement or increase in the number of antibodies and neutralizing antibodies 바카라 게임 웹사이트 a pretty nice increase. It's even a little bit higher than what we had after the third dose," Regev-Yochay said. "Yet, this is probably not enough for the omicron."In December, Sheba Medical Center started trialing a fourth dose of the vaccines for healthy people ahead of the rollout of the additional booster shot to at-risk people, making it the first study of its kind.Tracking the omicron surgeCOVID-19 deaths and cases are rising again at nursing homesHawaii may soon require travelers to have a COVID-19 boosterOmicron surge hasn't peaked nationwide, 'the next few weeks will be tough,' surgeon general sayCan you reuse N95 and KN95 masks safely? Experts weigh inThe study included 154 health care workers who were given a fourth dose of the Pfizer/BioNTech vaccine, 120 who were given a fourth dose of the Moderna vaccine and a control group of workers who were not given fourth doses.Regev-Yochay said that although the researchers saw an increase in antibodies among those who got fourth doses, the level of antibodies needed to protect against infection from omicron "is probably too high for the vaccine, even if it's a good vaccine." Still, she said that slightly fewer infections were observed among those who got the vaccine, compared with the control group.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 was no significant difference among those who received the Pfizer/BioNTech dose versus Moderna, Regev-Yochay added."I think that the decision to allow the fourth vaccine to vulnerable populations is probably correct," she said. "It may give a little bit of benefit, but probably not enough to support the decision to give it to all of the population, I would say."
Video above: SCOTUS blocks vaccine or test rule for business
Early data out of Israel suggests that a fourth dose of either the Pfizer/BioNTech or Moderna coronavirus vaccine can bring an increase in antibodies 바카라 게임 웹사이트 more than what's been seen after a third dose 바카라 게임 웹사이트 but it still might not be enough to protect against breakthrough infections caused by the omicron variant.
"These are very preliminary results. This is before any publication, but we're giving it out since we understand the urgency of the public to get any information possible about the fourth dose," Dr. Gili Regev-Yochay, director of the Infection Prevention and Control Unit at Sheba Medical Center, told reporters during a virtual news conference Monday about the data.
"We have a follow-up of the Pfizer vaccine for two weeks now, and we have a follow-up of the Moderna vaccine just for one week at this time point. And what we see is that the Pfizer vaccine, after two weeks, you see an enhancement or increase in the number of antibodies and neutralizing antibodies 바카라 게임 웹사이트 a pretty nice increase. It's even a little bit higher than what we had after the third dose," Regev-Yochay said. "Yet, this is probably not enough for the omicron."
In December, Sheba Medical Center started trialing a fourth dose of the vaccines for healthy people ahead of the rollout of the additional booster shot to at-risk people, making it the first study of its kind.
Tracking the omicron surge
The study included 154 health care workers who were given a fourth dose of the Pfizer/BioNTech vaccine, 120 who were given a fourth dose of the Moderna vaccine and a control group of workers who were not given fourth doses.
Regev-Yochay said that although the researchers saw an increase in antibodies among those who got fourth doses, the level of antibodies needed to protect against infection from omicron "is probably too high for the vaccine, even if it's a good vaccine." Still, she said that slightly fewer infections were observed among those who got the vaccine, compared with the control group.
There was no significant difference among those who received the Pfizer/BioNTech dose versus Moderna, Regev-Yochay added.
"I think that the decision to allow the fourth vaccine to vulnerable populations is probably correct," she said. "It may give a little bit of benefit, but probably not enough to support the decision to give it to all of the population, I would say."
